Neuberger Berman Group
BCRX icon

Neuberger Berman Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Neuberger Berman Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$154K Buy
15,394
+4,819
+46% +$43.6K ﹤0.01% 2207
2026
Q1 		$101K Buy
+10,575
New +$82.1K ﹤0.01% 2073
2014
Q4 		– Sell
-11,521
Closed -$112K – 1644
2014
Q3 		$112K Buy
+11,521
New +$141K ﹤0.01% 1618

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Neuberger Berman Group's BCRX Position: Q2 2026 in Review

Neuberger Berman Group increased its BioCryst Pharmaceuticals (BCRX) stake by 46% in Q2 2026, buying an estimated $43.6K and bringing the position to 15,394 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #2207.

Neuberger Berman Group first reported a position in BCRX in Q3 2014 and has held it in 3 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Neuberger Berman Group held 15,394 shares of BioCryst Pharmaceuticals worth $154K as of Q2 2026.
  • Neuberger Berman Group bought 4,819 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $43.6K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2207 holding.
  • Neuberger Berman Group first reported a position in BioCryst Pharmaceuticals in Q3 2014 and has held it in 3 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.